Index

abdominal examination, *Box 1.14, Fig 1.13*
abdominal mass, *photo 500*
abdominal pain, 324, 377, 383, *Fig 11.1*
abnormalities
  diagnosis in early pregnancy, 218–22, 232, 242–4
  fetal presentation, 374–5, *photos 393*
  in neonate, 291, *Tables 8.11, 8.12*
  labour, 263, 369–74, 387
Aboriginal women's health, 52, 64, 81, 192, 311
abortion, 320, 321, 324
  hydatidiform mole, 322–4
  miscarriage, 321, *Table 9.4*
  pain, 325
  recurrent, 318–30
  termination of pregnancy, 411–14
abuse, 99–104, *Tables 3.1, 3.2*
  childhood sexual, 99, 450, *Boxes 12.13, 12.14*
  domestic violence, 103–4, *Fig 3.1*
  examination, 111
  female genital mutilation, 62, 68, 99, 246–7
  pregnancy, 246
  presentation, *Fig 3.1*
  sexual, 99, 104–14, *Box 3.1*
  teenagers, 206
  women in minority groups, 68
accidental haemorrhage, 333, 383
acute pelvic pain, 476–8, 491, 573, *Table 13.3*
adenomyosis, 510
adolescence, 18–97
  adrenarche, hormones, 151–3
  bleeding problems, 197–200
  clinical presentations, 197–200
  communication, *Box 5.1*
  contraception, 203
  dysmenorrhoea, 201
  legal issues, 207
  pregnancy, 203–7
  psychological development, *Table 5.1*
  risk taking, 190–3, *Boxes 5.2, 5.3, 5.4*
adrenal hyperplasia, congenital, 175
adrenal neoplasms, 198
adrenal steroids, 148, 151, 336, *Figs 4.14, 9.3*
age
  at first pregnancy, 223–4
  of menarche onset, 197
  of puberty onset, 151–3
  and subfertility, 454–5, 465
  trisomy 21 risk, 213, 242, *Box 6.11*
ageing, 52, 600–14, *Box 17.4*
  body image, 88
  common disorders, *Boxes 17.1, 17.2*
  falls, 605–6, *Box 17.3*
  mental health, 134
  mood, 117–18
  population, *Table 17.1*
  prescribing for the elderly, 33–4
alcohol, 71–2
  and pregnancy, 72–4, *Box 2.2*
alpha fetoprotein
  diagnosis of neural tube defects, 215
ambiguous genitalia, 175–82, *Box 4.1, Table 4.8*
amenorrhoea, 171, 466–71
  delayed puberty, 198
  'post-pill', 402, 468
  secondary, *Box 13.2*
amniocentesis, 220, 342
amniotic fluid, 234
  chorioamnionitis, 318, 336, 339
  disorders of volume, 332, 335, 339, *Box 9.4*
  embolus, 391
  index (AFI), 332, 334
  meconium staining, 266, *Fig 8.3, Table 8.2*
  production, 234, *Box 9.4*
amniotic membranes
  rupture, 367
  sweeping, 368
anaemia, 239, 340
anal sphincter damage in childbirth, 551
analgesia in labour, 269, *Table 7.3*
anatomy
  abdomen, *Fig 1.13*
  lower uterine segment, *Fig 18.2*
  pelvic floor, 540, *Fig 15.10*
  pelvic organs, 15.10, 18.2, *Figs 1.2, 1.3*
  pelvis, 18.1, *Fig 7.2*
  ureter, *Fig 18.1*
  vulva, *Fig 1.1*
androgens
  fetus, 150
  masculinisation at birth, 177
  women, 159–60, 522, *Fig 4.5*
androstenedione, 160
anencephaly, 150, 170
anorexia nervosa, 90
anovulation
  menopause, 153, 159
  menorrhagia, *Box 14.4*
  oligomenorrhoea, 466
  polycystic ovarian disease, 469
  puberty, 153, 197
antenatal blood tests, *Box 6.10*
antenatal booking examination, 24
antenatal care, 28, 234–6
antenatal classes, 247, *Box 3.6*
antenatal complaints, common 247–51
antenatal counselling, genetic 223–30

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

antenatal shared care card, *Fig 6.10*
antenatal visit, first, 22–4
antepartum haemorrhage, 335, 383
antibiotics, prophylactic, 338, 405
anticoagulation
  postpartum, 378
  pregnancy, 340, 353
  pre-operative, 618
anti-D immunoglobulin, 343
antiphospholipid antibodies, 319, 330, 340
anxiety, 121
Apgar score, *Table 8.1*
artificial rupture of membranes, 367
assault, injury from, *Table 3.3*
assisted delivery, 375, *Fig 10.3*
  effects on baby, *photos 393*
assisted reproductive treatment, 326, 459–61
asthma, in pregnancy, 345, *Table 9.6*
autoimmune disease, in pregnancy 341
autonomy for women, 58

bacterial vaginosis, 318, 336, 339, *photo 499*
bad news, delivering, *Box 3.8*
Bartholin's cyst, *photo 145*
beneficence, 59
behaviour, abused women, stages of change, *Table 3.2*
biophysical profile, 334–5, 358
Bishop score, *Table 10.1*
bisphosphorate, *Fig 14.1*
bleeding, vaginal
  abnormal, 565, 568, *Box 14.2*
  childhood, 184
  in early pregnancy, 320, 322
  heavy, 486, 509, *Boxes 14.2–14.4, 14.8, 14.9, 14.12, Tables 13.6, 14.1*
  in late pregnancy, 383–5
  postmenopausal, 553, 568, *Box 15.1, Table 15.5*
  postpartum, 386–7, *Boxes 11.1–11.3*
blood disorders
  menorrhagia, 511
  in pregnancy, 340
blood pressure
  measurement in pregnancy, 238
  raised in pregnancy, 359, 354–63
'blues', 129
body image, 76, 84, 85, 88, 596
body language, *Box 1.5*
bonding, 176, 193, *Box 5.4*
bone mineral density, 526, *Figs 14.1, 14.2*
  DMPA effect on, 402
bowel symptoms and cancer, 571, 573
brain
  dementia, 611–13, *Table 17.3*
  hormonal effects on, 116
  mental assessment, 611, *Box 17.4*
Braxton Hicks contractions, 248
breast
  benign disease, 529–40
  calcification, *Figs 16.2, 16.3*
  cancer, 583–95
    classification, *Box 16.3*
    clinical presentation, *Box 16.1, Figs 16.2, 16.3*
    investigations, *Box 16.2*
    and HRT, 589
    risk factors, *Table 15.1*
    recurrence, 590, 591, 592, *Tables 16.6–16.10*
    screening, 506–9, *Table 16.4*
  changes, *Box 1.13*
  concerns, 454
  ductal carcinoma in situ, 584–5, *Table 16.5*
  examination, 13–14, *Boxes 1.12, 1.13, Figs 1.4–1.12*
  feeding, 302–5, *Boxes 8.3, 8.4, Fig 8.8*
    difficulties, 379, *Tables 10.2–10.4*
  investigation, *Figs 15.1–15.4, 15.6–15.9*
  lump, 529, 530, 532, 533, *Fig 15.5*
  mastitis, *photo 498*
  nipple discharge, 537–8, *Table 15.2*
  pain, 535–6
  pre-cancer, 583–6
  pregnancy changes, 247–8
  problems, 529–40, *Table 10.3*
  prosthesis, 508
  screening, 506–9, *Table 16.4*
  ultrasound, 583, *Figs 15.7, 15.8*
breech presentation, 374–5
brow presentation, 374, *Fig 10.2*
bulimia nervosa, 90

caesarean delivery, 376, 623, *Boxes 10.1, 10.2*
calcium, 79, 526
cancer, 557–8, *Figs 15.6–15.9, photo 502*
  abnormal bleeding, 562, 564, 565, 568, 573, 574, 576, 588, 591, 593
  breast, 583–95, *Table 15.1, Figs 16.15, 16.16*
  causes, 222, 557
  cervical, 565–9
  chemotherapy, 579–81, 592–4
  endometrial (uterine), 568–70, *Table 16.2*
  growth, 557–8, 579
  ovarian, 570–4
  premalignant change, 558–65
  psychological effects, 595–7
  staging, survival, spread, 581–3, *Table 16.3*
  treatment, 577–81
  trophoblastic disease, 322–4
  vaginal, 576–7
  vulval, 574–6
candidiasis, 423, 441–2

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

caput formation, 256, *Fig 7.3*
cardiac disease, 353–4, *Box 9.6*
cardiotocography (CTG), 333–4, *Figs 7.9, 7.10, Table 7.2*
cardiovascular system in pregnancy, 352–3
carpal tunnel syndrome, 248
cerebral palsy, 335
cervical smear, 18–19, *Fig 1.15*
cervix, uterine, *photos 144*
  abnormalities, *photos 501*
  cancer, 565–8
  cytology, *Table 16.1*
  discharge, *Table 12.6*
  effacement, 367, *Fig 7.6*
  infections, *Table 12.6*
  intraepithelial neoplasia, 558, *photo 501*
  labour, changes in, *Fig 7.6*
  polyp, *photo 145*
  postmenopausal, *photo 144*
  'ripeness', 367, *Fig 7.6, Table 10.1*
  screening, 558, *Box 1.15, Fig 1.15*
  squamocolumnar junction, *Fig 16.1*
  stenosis, 563
chemotherapy
  for cancer, 579–81, 592–4, *Tables 16.9, 16.10*
  for ectopic pregnancy, 326
chickenpox, 229
child sexual abuse, 99
  long-term effects, 450–2
childbirth, *Fig 7.8*
  analgesia, *Table 7.3*
  assisted, 375–6, *Fig 10.3*
  choice of mode, 365, *Boxes 10.1, 10.2*
  experiences, 253
  hormones, *Table 4.4*
  monitoring, *Figs 7.7, 10.1*
  normal progress, 265–72
  operative delivery, *Fig 10.3*
  positions for, *Fig 7.12*
children
  female development, 184–6
  vulvovaginitis in, 186–8
chlamydia, *Table 12.6*
  in neonate, *Table 8.10*
  pelvic inflammatory disease, 495, *photo 503*
  in pregnancy, 318, 336, *Table 6.2*
chloasma, 250
choice for women, 54, 61, 365, 407
chorioamnionitis, 318, 336, 339
choriocarcinoma, 324
chorionic villus sampling (CVS), 218–20, *Fig 6.2*
chromosome problems, 210–22
  ambiguous genitalia at birth, 175–82
  amniocentesis, 220–1
  chorionic villous sampling, 218–20, *Fig 6.2*
  cystic fibrosis, 215
  fetal loss, 318–19
  fragile Xq27.3, 214
  mosaicism, 213
  small for dates baby, 327–31
  subfertility, 454–6
  SRY, 180
  trisomy 21, 213, *Box 6.11*
  XO (Turner), 180, 213
  46XX, 177
  46 XY, 178–9
chronic pelvic pain, 478–80, *Box 13.5, Tables 13.4, 13.5*
clitoromegaly, 177, 467, 474, *photo 308*
clomiphene, 459
coagulopathy in pregnancy, 349, 357, 385–7
cognitive impairment, 610–14
collapse around delivery, 388–91, *Box 11.4*
combined oral contraceptive (pill), 396–400, *Boxes 12.1–12.4, Tables 12.1, 12.3*
communication
  with abused women, 101
  with adolescents, 189, *Box 5.1*
  of bad news, 140–1, *Box 3.8*
  body language, *Box 1.5*
  effective, 7, *Box 1.6*
  with the elderly, 615
  history taking, 9–10, *Boxes 1.7–1.11*
  improving, 4, 7, *Boxes 1.4, 1.8*
  informed consent, 6
  interviewing, 6–8, *Boxes 1.2, 1.3*
  litigation, 6
  with those in middle years, *Box 14.1*
  with new parents, 301–2
  providing information, 5–6
  unplanned pregnancy, 412
  woman-centredness in, 4, *Box 1.2*
conception, 160–7, *Fig 4.6*
  assisted, 459–61
  implantation, 163
confidentiality
  ethics and autonomy, 63
  sexual history, 9–11
congenital abnormalities, 212, *photos 306–8*
  adrenal hyperplasia, 177
  anticonvulsants, 226–7, 346–7
  counselling, 210–12, 223–30
  cysts, 171
  diabetics, 226, 351–2
  drugs, 216–18, *Box 6.2, Fig 1.21, Table 6.1*
  female genital tract, 173, *Fig 4.12*
  miscarriage, 318–19
  perinatal morbidity/mortality, 311, 327, 335
  prenatal detection of, 218–21, 242–4, *Box 6.3*
consent, informed, 6, 58, 120, 207
contraception, 395–410, *Boxes 12.1–12.7, 14.10–14.11, Tables 12.1, 12.2*
  summary of, *Table 12.3*
  in adolescence, 203

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

contractions
Braxton Hicks, 248
uterus in labour, 254, 256, 371
Coombs' test, 343
cord; *see* umbilical cord
corpus luteum, 153, 161
cyst, 491
cosmetic surgery, 91
counselling
genetic, 210–12, *Box 6.1*
postnatal, 298–301
pre-pregnancy, 223, *Box 6.4*
psychosexual, 9, 94–5, 446, 452, 479
couvelaire uterus, 385–6
cryptomenorrhoea, 171
culture (ethnicity), 8, 52, 61–2
Cushing's syndrome, 474
cystic fibrosis, 215
cystocele, 542
cysts
androgen-producing, 177
congenital, 171, *photo 503*
ovarian, 491–5
polycystic ovary syndrome, 469–70
cytology, *photos 501*
cervical, 558, *Table 16.1*
office, *Box 12.12, Table 12.10*
cytomegalovirus (CMV) infection, 229, 313
cytotoxic therapy
for cancer, 579–81
for ectopic pregnancy, 325–7
for trophoblastic gestational disease, 323

death, 139–43, 615, *Boxes 3.7, 3.8*
decisions, clinical, 40, 46, 58
dehydroepiandrosterone, 151, 159
dehydroepiandrosterone sulphate, 151,159
dementia, 611–13, *Box 17.4*
and delirium, *Table 17.3*
depression, 117–21, *Box 3.3*
ageing and, 134, 614
cancer and, 596–7
menopause and, 133
postnatal, 129, 131–2, *Fig 3.8*
women, 51, *Box 3.3*
dermoid cyst, 494, *Box 13.5, photo 500*
development
body systems in fetus, 168–75
normal female, 184–6
diabetes
baby of diabetic mother, 332, *photo 307*
gestational, 351–2
pre-pregnancy, 226
diary
menstrual, *Fig 5.3*
premenstrual, *Fig 3.7*
urinary, 547
discharge
cervical, *Table 12.6*
nipple, 537–8, *Table 15.2*
office cytology, *Table 12.10*
vaginal, 421–3, 186, 574, 576, *Table 12.5*
dilatation of cervix and curettage of uterus, 322, *Box 14.7*
disabilities, women with, 66
disseminated intravascular coagulation (DIC) in pregnancy, 357
Doppler blood flow studies, 334
douching, 415, 497
Down syndrome, 241, 243
drug abuse, 68–75, 192
drugs
and ageing, 614
classification, *Box 1.17*
complications, 624
and the elderly, 33–4
epilepsy, *Table 9.7*
and hirsutism, *Box 13.4*
and lactation, 32
in pregnancy, 30–2, 74–5, 225–6, 336–8, 353, *Boxes 1.17, 9.7, Table 9.7*
prescribing errors, *Box 1.1*
and prolactin increase, *Box 13.3*
teratogenic, *Table 6.1*
ductus arteriosus, 274
dying, 139–43
dysfunctional uterine bleeding (DUB), 515, *Tables 14.2,14.3*
dysgerminoma, 178, 573
dyskaryosis, 559
dysmenorrhoea, 201, 481, 495
dyspareunia, 171, 435, 447

eating disorders, 90–1
eclampsia, 359, 411
ectopic pregnancy, 325–7, *photo 498*
Edinburgh Depression Scale, 129, *Fig 3.8*
embolus, 390–1
embryology, 167–75, *Tables 4.6, 4.7*
cardiovascular system, 168, *Fig 4.9*
central nervous system, 168–70, *Fig 4.10*
genital tract, 170–5, *Figs 4.11–4.13*
emergencies
inversion of the uterus, 389, *Fig 11.4*
maternal collapse, 388–91
neonatal resuscitation, 275–8
postpartum haemorrhage, 386–7
prolapsed cord, 388, *Fig 11.3*
emergency contraception, 400
endometriosis, 481–4, *photo 503*
endometritis, 377
endometrium, 162
cancer, 568–70, *Table 16.2, photo 502*
hyperplasia, 564, *Table 16.2*

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

endometrium *(cont'd)*
polyps, *photo 498*
enduring power of attorney, 59
enterocele, 542
epidural anaesthesia, *Fig 7.11*
epilepsy, 226–7, 346–7, *Box 6.6, Table 9.7*
episiotomy, 271–2, *Fig 10.3*
ergometrine, 263, 362
ethics, 56–62
evidence-based medicine, 40–7, *Box 1.20, Figs 1.22, 1.23, Table 1.1*
examination; *see* physical examination
exercise, 85–8
external cephalic version, 374

faecal incontinence, 551–3, 609–10
female genital mutilation, 62, 99, 246–7
Ferriman-Gallwey Score, *Fig 13.1*
fertilisation
in vitro, 459–61
normal, 162
fertility
effects of age on, *Table 13.2*
lesbian parenting, 465
problems, 454–65
semen analysis, 463, *Box 13.1*
subfertility, 454–65
fetal alcohol syndrome, 72, 73, 225–6
fetus
abnormal presentation, 374–5, *Fig 10.2*
assessment of well-being, 333–5
blood sampling, 221, 343
breech presentation, 374–5
caput succedaneum, 256, *Fig 7.3*
cardiovascular system, 168, *Fig 4.9*
central nervous system, 168–70
delivery methods, Fig 10.3
development, *Figs 1.21, 6.5, Tables 4.6, 4.7, 6.4–6.5*
effects of drugs on, 30, *Fig 1.21*
engagement of head, *Fig 1.20*
fibronectin, 336
genital tract, *Figs 4.11–4.13, Table 4.8*
growth, 232–3, 327, *Table 6.5*
restriction 327–31, *Boxes 9.1–9.3*
haemoglobin, *Fig 4.8*
head (skull), suture lines and fontanelles, *Figs 7.3, 10.2*
heart monitoring 266, *Fig 7.9, Table 7.2, photos 392, 330*
intrauterine growth restriction, 288, 327–31, *Boxes 9.1–9.3, Fig 9.3, Table 8.8*
in labour, 256
loss of, *Fig 9.1*
macrosomia, 333
moulding of head, 256, *Fig 7.3*
movements, 333
organ development, *Table 4.7*
ovary, 148
perinatal mortality, 310–12, *Fig 9.1*
presentation/lie, 332, 374–5
pre-term delivery, 335–8
sexual differentiation, 150, *Fig 4.1*
small for gestational age, 288
smoking, effects on, 70, *Box 2.1*
ultrasound, 334, *Figs 6.4, 6.6–6.9, Table 6.4*
well-being, 333–5
fever, postpartum, 377
fibroids, 486–91, *Fig 13.2, photo 500*
degeneration, 486, 491
hormone treatments for, *Table 13.6*
pelvic mass, 484–6, *Fig 13.2*
in pregnancy, 486–7
risk factors, *Box 13.6*
FISH, 220
folate (folic acid), 78, 225, 346
follicle-stimulating hormone (FSH), 148, 155, 159, *Figs 4.4, 4.5*
follicular cysts, 491
foramen ovale, *Fig 8.1*
forceps delivery, 373, 374, *Fig 10.3*
forensic examination, 110, *Box 3.2, Fig 3.6*

galactorrhea, 468
Gardnerella vaginalis, *Table 12.5*
gender
and brain function, 116
disease differences, *Box 18.7*
discrimination, 59
ethical issues, 60–2
and health, 49–56
mental illness, 115
risk-taking differences, 192–3
in sport, 85–6
genes/genetic disorders, 210–22; *see also* syndromes
birth defects, causes, *Box 6.2*
in cancer, 222, 557, 589
counselling, 210–12, *Box 6.1*
cystic hygroma, *photo 306*
diagnosis, 221–2
antenatal, 329, *Figs 6.2, 6.3*
prenatal, 218, *Box 6.3*
family tree, constructing, *Fig 6.1*
male infertility, 464
neonate, 236
genitalia
ambiguous, 175–82
development, *Figs 4.11–4.13*
external and internal, 171–5
injury, 109–10
gestalt, 221
gestational age, by ultrasound, 241–2, 283
gestational diabetes, 241, 351–2

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

gestational trophoblastic disease, 322–4
gonadotrophin-releasing hormone (GnRH)
in infertility treatment, 460
in the life cycle, 149–55
gonads, fetal, and sex determination, 150
gonorrhoea, 425
PID 495–7
grief and loss, 135–9
group B streptococcal infection in pregnancy, 317–18
growth retardation, intrauterine fetal, 288, 327, *Boxes 9.1, 9.2, 9.3, Tables 8.8, 8.9, Fig 9.3*
growth spurt, adolescent, 196

haematocolpos/haematometra, 184
haematological changes in pregnancy, 339
haemorrhage
accidental, *Fig 11.1*
antepartum, 383–4
at delivery, 263
postpartum, 386–7, *Boxes 11.1–11.3*
secondary, 618
hair
hirsutism, 472–6
pubic, growth of, *Fig 4.3*
scalp, in pregnancy, 248
head, descent of fetal, 25–7, 256
heart
fetal development, 168
fetal monitoring in labour, *Fig 7.9, Table 7.2, photos 392*
disease, maternal, 352–4, *Box 9.6*
HELLP syndrome, 350
hepatitis, 421
in pregnancy, 228, 240, 315–16
hermaphrodite, 179
herpes, genital, 229, 426, 428–9, *photo 499*
in pregnancy, 229, 317
hirsutism, 472–6, *Box 13.4, Fig 13.1*
Ferriman-Gallwey model, *Fig 13.1*
history taking, *Boxes 1.9–1.11*
gynaecological, 9
obstetric, 22–4, *Box 6.9*
psychiatric, 116–17
sexual, 9, 11
HIV infection, 228, 240, 430–3
hormones, 148–60, *Table 4.1*; *see also* under individual hormones
in fetal life, 156
and menopause, 157, *Fig 4.5*
menstrual cycle, *Table 4.1*
and mood, 123
pregnancy, *Table 4.4*
hormone replacement therapy (HRT), 521–7
breast cancer, 589
endometrial ablation, 621–2
risk associated with, 524, *Table 14.4*
thrombosis, *Box 18.2*
and urinary symptoms, 547
human chorionic gonadotrophin (HCG)
fetus, 158, 150
gestational trophoblastic disease, 322
pregnancy test, 158, 231, 321
human papilloma virus (HPV)
genital warts, 427
Pap test, 559, 562
and neoplasia, 567
hydatidiform mole, 322–4, 331
hydramnios, 331
hydrops, fetalis, 316, 344
hydrosalpinx, 495, *photo 503*
hymen
development, 171
imperforate, 184, 486, *photo 308*
newborn, 185
hyperemesis gravidarum, 251, 348
hyperprolactinaemia, 468–9, *Table 15.3*
hypertension and pregnancy, 354–63, *Boxes 9.7–9.10, Figs 9.5, 9.6*
hypothalamic amenorrhoea, 470–1
hypothalamo-pituitary axis (HPO), 149–57
hypoxia, fetal, 254, 334, 375
hysterectomy, 622–3, *Boxes 18.5, 18.6, photo 500*
hysterosalpingogram, *Table 13.1*
hysteroscopy, 621
cancer detection, 568

immigrant women and health, 64–5
implantation, 163–4
in vitro fertilisation (IVF), 459–61
incontinence, *Table 15.4*
bladder neck support, *Fig 15.16*
cystometry, *Fig 15.17*
faecal, 551–3, 634, *Fig 15.19*
physical activity, 86
postpartum 378–9
stress incontinence, *Fig 15.14*
tension-free tape, *Fig 15.18*
urinary 544, 608
vesicovaginal fistula, 549, 568
incubation period, for STIs, *Table 12.4*
Indigenous women, 52, 63–4, 81, 192, 311
induction of labour, 367–9
infections
bacterial vaginosis, 318
cervical, *Table 12.6*
chickenpox, 229
chlamydia, 318
chorioamnionitis, 318
ytomegalovirus, 229, 313
group B streptococcus, 317–18
hepatitis B and C, 315–16
herpes simplex, 229, 317

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

infections *(cont'd)*
HIV/AIDS, 430–3
infertility, *Table 13.1*
intrauterine, 311, 318
listeriosis, 317, *Box 6.5*
maternal, 312–13, *Tables 9.1, 9.2*
parvovirus, 316–17
pelvic, 495–7
postpartum sepsis, 377
in pregnancy, 312–18, *Table 9.1*
pre-pregnancy, 227, *Table 6.2*
rubella, 228–9, 314
septic shock, 391
sexually transmitted, 414–15, *photos 499*
toxoplasmosis, 228, 315, *Table 6.3*
TORCH syndrome, 227
urinary, 241, 324
vaginal, 185–6, *Table 12.5*
varicella, 316
vulval, *Table 12.8*
vulvovaginitis, in children, 186–7
infertility, 454–62, 495
investigations, *Table 13.1*
male, 463–5
semen analysis, 463, *Box 13.1*
informed consent, 6, 58, 109, 207, 618
inhibin, 155
interpersonal and clinical skills
communication and interviewing, 2–11
physical examination, 12–21, 24–27, *Figs 1.1–1.19, Boxes 1.12, 1.13*
history taking, 9–11, 22–4
investigations, 21, *Box 1.16*
clinical reasoning, 22
intracytoplasmic sperm injection (ICSI), 464–5
intrauterine devices (IUDs), 404–6, *Box 12.7, photo 500*
intrauterine growth restriction (IUGR), 288, 327–31, *Box 9.1, Fig 9.3, Table 8.8*
intrauterine transfusion, 343
inversion of the uterus, 389, *Fig 11.4*
investigations, *Box 1.16*
antenatal, *Box 6.10*
iron supplements, 80
irritable bowel syndrome, *Table 13.4*
isoimmunisation, 341

jaundice
in the newborn, 280–1, *Boxes 8.1, 8.2, Fig 8.5, Tables 8.3, 8.4*
in pregnancy, 349

Kallmann's syndrome, 149
karyotyping indications, 198, 213, 319, 322, 329, 457, 464, 471
kernicterus, 344
Kleinfelter syndrome, 464
Kleihauer test, 344
Krukenberg tumour, 177

labour, 265–71, *Figs 7.4, 7.8*
abnormal, 369–74
anaesthesia/analgesia, 265, 268, 269, 391
assisted delivery, 375–6
cervical changes, *Fig 7.6*
choice for women, 365
delay, 369–74, *Fig 10.1*
delivery, *Figs 7.8, 7.12*
failure to progress, 366, 367, 369
induction, 367–9
infection, *Tables 9.1, 9.2*
management during, 268–72
normal progress, 254–9, *Fig 7.4*
observations, routine, *Table 7.1*
pain relief, 269, *Table 7.3, Fig 7.11*
partogram, *Fig 7.7*
phases of, 259–65
pre-term, 332, 335–8, *Box 9.5, Fig 9.4*
stages of, 261–3
sudden collapse, 388–91
third stage of, 263
women's experiences of, 253
lactation, 293, 302–5, 379, *Boxes 8.3, 8.4, Fig 8.8, Tables 10.2–10.4*
laparoscopy, 622, 628
for pelvic pain, 480, *Box 13.5*
large for dates, 331–3
law
domestic violence and the, 103
teenagers and the, 207
leiomyoma, 486–91
lesbian women, 65–6
fertility, 465–6
sexuality, 93
sexually transmissible infections, 433–4
libido, loss of, 446, 447, 449
lichen sclerosus, *Table 12.9*
lifestyle issues
alcohol and drugs, 68–75
weight and nutrition, 75–85
physical activity, 85–88
liquor, 234
amnii, production of, *Box 9.4*
excess (hydramnios), 331, 332, 333
meconium-stained, 278, *Table 8.2*
reduced (oligohydramnios), 334
listeriosis, 224, 317, *Box 6.5*
liver
in pregnancy, 348–9
disease 315–16
lochia, 296
loss
cancer, 595
in women's lives, 135–9, *Table 3.4*

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

of pregnancy, 318–20, *Table 9.3–4*
luteinising hormone (LH), 155
lymph nodes
breast cancer recurrence, *Tables 16.4, 16.7*
cancer, 587, 590–1

macrosomia, 332
magnesium sulphate, eclampsia, 359
male sexual problems, 449
maleficence, 57
malpresentations, 374–5, *Fig 10.2*
mammography, 506–8, *Figs 15.1, 15.2, 15.6–15.9, 16.2, 16.3*
Manchester repair, prolapse, 629
Marfan's syndrome, 354
mastectomy, 589, 590, *Table 16.6*
mastitis, photo 498
maternal mortality, 310–11, 349, 354
meconium
aspiration syndrome, 278–9, *Fig 8.4*
staining of liquor, *Fig 8.3*
medications in pregnancy, teratogenicity, 30, 31–2, *Fig 1.21*
membranes (amniotic)
amniotomy, 367
rupture, 261, 265
premature, 338–9
sweeping of, 368
menarche, 155, 197
Mendelson's syndrome, 623
menopause, 517–27, *Boxes 14.13–14.15*
hormones, 157, *Fig 4.5, Table 14.4*
osteoporosis, 526–7, 606–9, *Figs 14.1, 14.2, 17.1, 17.2*
premature, 471
menorrhagia
in adolescence, 198–201
in middle years, 509–17, *Boxes 14.2–14.12, Tables 14.1–14.3*
menstrual cycle, hormones, 151, *Fig 4.4, Table 4.1*
menstruation
absent (amenorrhoea), 466–71
blood loss assessment, *Fig 5.3*
heavy, 509–17, *Boxes 14.2–14.4, 14.8, 14.9, 14.12*
irregular, 153, 573
last, 519
onset of (menarche), 154, 197
painful, 201
problems, 466–71, 509–17
secondary amenorrhoea, 466, *Box 13.2*
mental health and illness, 114–34
mental status assessment, 610–11, *Box 17.4*
mid-life, stresses in, *Fig 3.9*
minority groups, 63–8
miscarriage, 320–2, *Table 9.4*
recurrent, 318–20
misoprostol (mifepristone-RU486), 368
mittelschmerz, *Table 13.3*
molar pregnancy, 322–4, 332
molluscum contagiosum, 186, 440
Monilia infection, *photo 499*
mood
and ageing, 134
hormone-related, 123–6
in pregnancy, 126–8, *Box 3.6*
menopause, 132–3, *Fig 3.9*
morbidity/mortality
gynaecological (PID), 495
maternal mortality, 310–11, 353, 383
perinatal mortality, 311, 335, *Fig 9.1, Box 9.5*
postpartum, 376–7
moulding of fetal head, 256, *Fig 7.3*
multiple pregnancy, 329, 331, 335, 356, 375, 460
myomectomy, 489–90

neonate/newborn
ambiguous genitalia, 175–82
adaptation at birth, 274–5, *Fig 8.1*
birth defects, *Box 6.2, Table 8.12*
birth weight, 283, *Table 8.5*
cardiovascular changes at birth, 168, *Figs 4.9, 8.1*
central nervous system, 168–70, *Fig 4.10*
common conditions, *Table 8.10*
congenital problems, 210, *Tables 8.10–8.12, photos 306–9*
examination, 288–9, 292–3
external cardiac massage, *Fig 8.2*
genetic evaluation, 221–2
gestational age, assessment of, 283
jaundice, 280–1, *Boxes 8.1, 8.2, Fig 8.5, Tables 8.3, 8.4*
major malformations, *Table 8.11*
meconium aspiration syndrome, 278–9, *Table 8.2, Figs 8.3, 8.4*
necrotising enterocolitis, 287, *Fig 8.7*
preterm infant, 284–8, *Box 9.5, Table 8.6*
respiratory distress syndrome, 285–7, *Fig 8.6, Table 8.7*
resuscitation, 275–8, *Table 8.1, Fig 8.2*
retinopathy of prematurity, 288
size, *Table 8.5*
small for gestational age, 288, *Tables 8.8, 8.9*
trauma, 333, *photos 393*
neural tube defects, 215–16, *photo 306*
embryo, 169–70, *Fig 4.10*
folate/folic acid deficiency, 225
nuchal translucency, 241
nicotine dependence, 69–71, *Table 2.1*

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

nipple
discharge, 537–8, *Table 15.2*
pain, 379, *Table 10.2*
nuchal translucency/fold scanning, 241
number needed to screen/treat, 35, 47
nutrition, 224, *Table 2.3*

obesity, 80–5
oblique lie, *Fig 1.19*
occipito-posterior (OP) position, 372
odds ratio, 43, 44, 45, 46
oestrogen(s)
at birth, *Table 4.4*
in contraceptives, 396
endometriosis, 482
endometrial cancer, 569
fibroids and, 488
in the life cycle, 148
and menopause, 157, 519
in the menstrual cycle, *Fig 4.4*
oligohydramnios, 234, 334
oligomenorrhoea, 466
oophorectomy
cancer, 572
hysterectomy, *Box 18.6*
operative delivery, effects on baby, *photos 393*
oral contraceptives, 396–400, *Boxes 12.1–12.4, 14.11, Table 12.1*
causing amenorrhoea, 468
for dysmenorrhoea, 201
for hirsutism, 475
for menorrhagia, 200, 516, *Box 14.11*
for polycystic ovarian syndrome, 470
post-coital, 400–1
post-pill amenorrhoea, 402, 468
progestogen-only, 399–400
organogenesis, *Table 4.7*
orgasm, 443, 448, 463, *Fig 12.2*
osteoporosis, 526–7, 606–7, *Figs 14.1, 14.2, 17.1, 17.2, Table 17.2*
ovary
benign tumours, 491–5, *Box 13.7*
cancer, 570–4, *photo 502*
corpus luteum, 161, 162, *photo 498*
cysts, 324, 341, 493, *Table 13.5, Box 13.7, photos 500, 503*
development, 148,180, 185, *Table 4.2*
failure, premature, 471
folliculogenesis, 170
hormone-secreting tumour, 177, 198
hyperstimulation, 460
hyperprolactinaemia, 468–9, *Box 13.3*
menstrual cycle, 171
ovulation, photo 498
physical activity, 84–8
polycystic, 459
removal, at hysterectomy, *Box 18.6*
breast cancer 593
rupture of cyst, 491
'streak' ovary, 170, 178, 198, *photo 309*
torsion, *photo 498*
ovulation, 455, 456, 459, *Fig 4.4, Table 13.1*
oxygen dissociation curve, *Fig 4.8*
oxytocin, 263, 368

Paget's disease, nipple, *Box 1.13, photo 502*
pain
abdominal, pregnancy 324–7
acute pelvic, 476–8, 497, 516, 573, *Table 13.3*
chronic pelvic, 478–80, *Table 13.4*
endometriosis, *photo 503*
nipple, *Table 10.2*
pelvic, 476–83
postpartum, 377–8
relief in labour, 269, *Table 7.3*
Pap test, 558–60, *Table 16.1*
in adolescence, 202–3
conducting the test, 18–19, *Fig 1.15*
request, *Box 1.15*
partogram, 261, 370, *Figs 7.7, 10.1*
parvovirus in pregnancy, 316–17
pelvic floor/pelvis
anatomy, 540, *Figs 1.2, 1.3, 7.1, 7.2, 15.10*
disorders, 540–52
examination, 16–18, *Fig 1.16*
incontinence, 542
urinary, 544–51, *Figs 15.14–15.17, Table 15.4*
faecal, 551–3, *Fig 15.19*
inflammatory disease (PID), 495–7, *Box 13.8, photos 503, 405*
labour, 254, *Figs 7.1, 7.2*
muscle training, 548
mass, 484–97, 571, 573, *Table 13.5*
organs, *Figs 1.2, 1.3, photos 145, 503*
pain, 476–84, *Tables 13.3, 13.4*
postpartum changes, 296
prolapse, 541–4, *Figs 15.11–15.13*
surgical repair, 544, 553, 629
varicosities, photo 503
perinatal morbidity/mortality, 311, 335, *Box 9.5*
pethidine, in labour, *Table 7.3*
pharmaceutical errors, 2–3, *Box 1.1*
physical activity, 85–8
physical examination 12, *Box 1.12*
abdominal, 14–16, 24–25, 26, *Box 1.14, Fig 1.13, photo 500*
antenatal, 24–8, 237–8
breast, 13–14, *Box 1.13, Figs 1.4–1.12*
forensic, 110–12, *Fig 3.6, Box 3.2, Table 3.3*
labour, 266
newborn, 288–9, 292–3
pregnant abdomen, *Figs 1.17–1.20*

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

vaginal/pelvic, 16–18, *Figs 1.14, 1.16–1.18, photo 144*
physically impaired women, 66
pinworms, 187, *Fig 5.1*
pituitary hormones, 149, 151,157
placenta, 233–4, *photo 392*
abnormalities, *Fig 7.5*
abruption, 385, *Fig 11.1*
accreta, 387
delivery, 257, 263
development, 164–5, *Fig 4.7*
functions, *Table 4.5*
hormones, *Table 4.4*
manual removal, *Fig 11.2*
morbidly adherent, 387
praevia 385, *Fig 11.1*
retained, 265, 387
on ultrasound, 242, 384
polycystic ovarian syndrome, 459
polyhydramnios, 332–3, 335
population, demography of ageing, *Table 17.1*
post-coital contraception, 400–1
postnatal depression, 129, 131–2, *Fig 3.8*
postnatal period, 295–302, *Tables 8.13, 8.14*
postmenopausal bleeding, 553–5, 568, *Table 15.5, Box 15.1*
postpartum breast problems, *Table 10.3*
postpartum collapse, *Box 11.4*
postpartum problems, common, 376–81, *Table 8.13*
postpartum fever, 377
postpartum haemorrhage, 386–7, *Boxes 11.1–11.3*
postpartum incontinence, 378–9
postpartum pain, 377
postpartum psychological problems, 379
postpartum vaginal bleeding, 378
post-pill amenorrhea, 402, 468
pre-eclampsia, 355–63, *Boxes 9.8–9.10, Figs 9.5, 9.6*
pregnancy
abuse during, 246
acute abdominal pain, 324–5
advice, 247–51
alcohol, 72–4, *Box 2.2*
autoimmune disease, 341
backache, 247
bleeding in early, 320–2
blood tests, 239–41, *Box 6.10*
care, 234–45
carpal tunnel syndrome, 248
clinical manifestations of, 230–1, *Box 6.7*
ommon complaints, 247–51
dating, 328,
early loss of, 318–20, *Table 9.3*
ectopic, 325–7, *photo 498*
examination, 237–8
female genital mutilation, 246–7
fetus and placenta development, 232–3
genetic tests, 218–21
haematological changes, 339
health record, *Fig 6.10*
history, *Box 6.9*
hormones, 157, *Table 4.4*
infections, 227–9, 312–18, 330, 335, *Tables 6.2, 9.1, 9.2*
investigations for, 231, *Box 6.10*
large for dates, 331–3
leg cramps, 249
loss of, 318–20, *Table 9.3*
maternal collapse, 388–91
medical problems, 339–63
models of care, 28, 235
mortality and morbidity, 310–11
nutrition, 224–5
parental age, 223–4
physiological changes, 31, 357
pre-pregnancy counselling, 223–30
preterm labour, 335–8, *Fig 9.4*
preterm prelabour rupture of membranes, 338–9
prolapse, 541
prolonged, 367
renal disease, 347–8
Rhesus disease, 341–5, *Table 9.5*
risk, 83, 236, *Box 6.8*
signs and symptoms, *Box 6.7*
skin changes, 249–50
small for dates, 327–31
teenage, 203–7
termination, 207, 411–14, *Fig 12.1*
tests, 231, 238, *Box 6.10, Table 6.4*
tiredness, 250
ultrasound, 241–2
unplanned, 411–14
vomiting, 251
premalignant change, 558–65
breast, 584–6, *Table 16.5*
cervix, 558–64, *Table 16.1*
endometrium, 564, *Table 16.2*
ulva, 565
premature labour, 332, 335–8
premature ovarian failure, 471
premenstrual dysphoric disorder (PMDD), 125–6, *Box 3.5*
premenstrual syndrome, 123–5, *Box 3.4, Fig 3.7*
prenatal diagnosis, 242–4
pre-pregnancy counselling, 223–30, *Box 6.4*
pre-pregnancy infection testing, 227–9, *Table 6.2*
prescribing, 28–34
errors, 2, *Box 1.1*
for the elderly, 33
during lactation, 32
pharmacokinetics, 29

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

prescribing *(cont'd)*
pregnancy and drugs, 30, *Fig 1.21*
self-medication, 28
preterm infant, 284–8, *Box 9.5*
respiratory distress syndrome, 285–7, *Fig 8.6, Table 8.7*
survival and disability, 284–5, *Table 8.6*
preterm labour, 335–8, *Fig 9.4*
preterm rupture of membranes, 338–9
progestogens
contraception, 401–3, *Boxes 12.5, 12.6, Table 12.2*
endometriosis, 481–4
hormone replacement therapy, 521, *Box 14.15*
in the life cycle, *Tables 4.1, 4.4, Figs 4.4, 4.5*
for menorrhagia, *Table 14.2*
premenstrual syndrome, 124
prolactin
hyperprolactinaemia, 468–9, 538, *Box 13.3, Table 15.3*
in the life cycle, 155–6
prolactinoma 469
prolapse 540–4
cord, 388, *Fig 11.3*
uterovaginal, *Figs 15.11, 15.12*
uterus, *photo 145*
vaginal vault, *Fig 15.1*
prostaglandins
dysmenorrhoea, 201
labour induction, 367
postpartum haemorrhage, *Box 11.2*
proteinuria
pre-eclampsia, 355
in pregnancy, 241, 347
renal disease, 347
pruritus
pregnancy, 250, 349
vulval, 434
pseudomyxoma peritonei, 494
psychiatric assessment, 116
psychological effects or problems
cancer, 595–7
menopause, 132–4, *Fig 3.9*
obesity, 82
postpartum problems, 379
pregnancy 126–32, *Box 3.6*
puerperal psychosis, 129–31
psychosexual problems, 442–52
puberty, 151–3, 194–7; *see also* adolescence
delayed, 198
normal events, *Fig 5.2*
precocious, 197–8
Tanner chart, 196, *Figs 4.2, 4.3*
pulmonary embolism in pregnancy, 339–40, 390
pulmonary hypertension in pregnancy, 353
pyelonephritis, 241, 247, 347
pyosalpinx, 496
pyrexia, postpartum, 377

quickening, 235

radiotherapy, for cancer, 578–9, 591–2
randomised controlled trial, 35, 36, 41
rape, 104–5; *see also* sexual assault
rectocele, 542
red degeneration, 325, 486
regional anaesthetic, 270
relaxin, 157
renal disease in pregnancy, 335, 347–8, *Table 9.8*
reproductive technology, 54, 60, 459–61
reproductive tract development, 170–5, *Figs 4.11–4.13*
research
evidence-based, 39–47, Box 1.20, *Figs 1.22, 1.23, Table 1.1*
women/gender differences, 50, 62, 626, *Boxes 18.7, 18.8*
respiratory distress syndrome, 285–7, *Fig 8.6, Table 8.7*
respiratory system, in pregnancy, 345
retraction of uterine muscle, 254
Rhesus disease, 341–5, *Table 9.5*
risk
absolute, 46
risk-taking in adolescence, 190–3, *Boxes 5.2–5.4*
from obesity 82–3
factors/assessment in pregnancy, 23–4, 236, *Box 6.8*
sexual, 96, 420
rubella
pre-pregnancy testing, 228–9
in pregnancy, 239, 314
ruptured membranes, 338–9

safe sex, *Box 12.10*
salpingo-oophorectomy, *Table 18.1*
salpingostomy/ectomy, 326–7
scabies, vulval infestation, *Table 12.8*
screening, 34–9, 61
breast, 506–9, 529, *Table 16.4*
cervical, 558–60
chlamydia, 202
congenital abnormalities, 222
criteria, *Box 1.18*
definitions used in, *Box 1.19*
gestational diabetes, 241, 351
in pregnancy, 239–41
infection 312–18, *Tables 6.2, 9.2*
ultrasound, 241–2
self-esteem, 84, 90, 189
semen analysis, 463, *Box 13.1*
septic shock, 391

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

sex determination, 150, *Fig 4.1*
sex hormone binding globulin (SHBG), 156, *Table 4.3*
hirsutism, 472, 475
sex offenders, 107–8
sexual activity/behaviour, 93–6, 442–4, *Table 2.4*
in adolescence, 191
influences on, *Table 2.5*
problems, 444–6, *Table 12.11*
male, 449, *Table 12.11*
postpartum, 297
in pregnancy, 249
normal response, *Fig 12.2*
safe sex, *Box 12.10*
terms for, *Table 12.4*
sexual assault or abuse, 104–14, *Box 3.1, Fig 3.2–3.5, Table 3.3*
in childhood, 450, *Boxes 12.13, 12.14*
sexual characteristics, secondary, 151, 197
sexual differentiation, 150
sexual dysfunction, 446, *Table 12.11*
sexual history, 9
sexual identity, 93
sexual orientation, 93
sexuality, 9, 92–6
and ageing, 614
and cancer, 596
impact on health, 95–6
in pregnancy, 249
postpartum, 297
sexually transmissible disease, 414–41, *Boxes 12.8, 12.9, photo 499*
in the child, 186
examination, 418
herpes, 426–9
HIV/AIDS, 430–3
incubation periods, *Table 12.4*
investigations, 418–20
in lesbians, 433–4
management, 420–1
notifiable, 421, *Box 12.11*
safe sex, *Box 12.10*
syphilis, 429–30
in pregnancy, 430
and teenagers, 202
warts, 429
shoulder dystocia, 333
'show', 265
sickle cell disease, 239, 250, 329, 340
side effects
of chemotherapy, 580–1
of radiotherapy, 579
skin, in pregnancy, 249–50
small for dates/gestational age (IUGR), 288, 327–31, *Boxes 9.1, 9.2, Tables 8.8, 8.9*
smoking, 69, 71, 329, 547, *Table 2.1*
in pregnancy, 70, *Box 2.1*
social factors, 52–3, 59, 63, 75, 86
in adolescence, 189, *Table 5.1*
in pregnancy, 235
teenage, 205
sperm
anti-sperm antibodies, 465
insemination, 461, 465
intracytoplasmic injection, 464–5
tests, 463, *Box 13.1, Table 13.1*
spermicide, 406
spina bifida; *see* neural tube defects
spironolactone, 476
sterilisation, 407, *Table 12.3*
steroids
adrenal, 151, *Fig 4.14*
antenatal administration, 336, 338, 362, *Fig 9.4*
stillbirth, 311, 316, 317, *Fig 9.1*
'streak' ovary, 170, 178, 198
stress incontinence, 547–8, *Fig 15.4*
subfertility, 454–66, *Box 13.1, Tables 13.1, 13.2*
suburethral sling, *Fig 15.18*
sudden infant death syndrome (SIDS), 294
suicide, 193
supine hypotensive syndrome, 24, 248
surgery, 618–25, *Figs 18.2–18.10*
for cancer
genital, 577–8
breast, 589–91
common procedures, 621–3, *Table 18.1*
operative considerations, *Box 18.2*
risks, 619–20, *Box 18.1*
syncytiotrophoblast, 164
syndromes
androgen insensitivity, 179
Angelman, 214
antiphospholipid, *Box 9.2, Table 9.3*
Asherman's, 468
Eisenmenger's, 353
gestalt, 221
fetal alcohol, 72, 225, *Box 2.2*
HELLP, 350
Kallmann's, 149
Kleinfelter, 464
Marfan's, 354
Meig's, 494
Mayer-Rokitansky-Künster-Hauser, 180
non-polyposis coli, 222
ovarian hyperstimulation, 460
polycystic ovarian, 459
Prader-Willi, 214
Swyer, 178
TORCH, 227
Turner, 180, 213, *Box 6.2, photo 308*
syntometrine/syntocinon, 263
induction, 368

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

syphilis, 429, *Table 12.7, photo 499*
in pregnancy, 430, *Box 6.10, Table 6.2*
systemic lupus erythematosus, 340–7

tamoxifen, 592–3
Tanner chart, *Figs 4.2, 4.3*
tears, perineal, 263
teenagers, 197–208
pap smears, 202–3
pregnancy, 203–7, 193
teratogenesis, 31, 216–18, *Box 1.17, Fig 1.21, Table 6.1*
teratoma, benign cystic, 494, *photo 500*
termination of pregnancy, 412–14, *Fig 12.1*
testes
absent/underdeveloped, 178
fetal, 150, *Figs 4.1, 4.11*
testosterone
amenorrhoea, 467
in hormone replacement therapy, 522
genital development, 173
hirsutism, 467
in the life cycle, 150, 160
thalassaemia screening, 239
thrombocytopenia, 340–1
HELLP, 350
iso-immune disease, 341
thrombosis, 619
pre-eclampsia, 355–63, *Boxes 9.8–9.10*
postoperative risk, *Box 18.3*
postpartum, 339–40, 378
in pregnancy, 310, 339–40
prophylaxis, 619–20, *Boxes 18.3, 18.4*
thyroid in pregnancy, 350–1
tocolysis, 336–8
TORCH syndrome, 227
torsion of ovarian cyst, 491, *Table 13.3*
toxic shock syndrome, 496
toxoplasmosis
prevention, 228, *Table 6.3*
infection, 315, *Table 9.2*
transverse lie, 25, *Fig 1.19*
trial of scar, 390
Trichomonas, 417, 423
trisomy 21, 213, 243, *Box 6.11*
tumour marker, 492, 573, 595
tumour suppressor genes, 557
Turner syndrome; *see* syndromes
twins, 329, 331, 335, 375, 460, *Box 9.9*

ultrasound
in adolescence, 200
anal, 552, *Fig 15.19*
ambiguous sex at birth, 181
anomalies, fetal, *Box 9.3*
breast, *Figs 15.7, 15.8*
bleeding in pregnancy, 321, 384
Doppler, 334, *Box 9.3*
in early pregnancy, 231, *Fig 6.4*
faecal incontinence, 552, *Fig 15.19*
fetal, 334, *Figs 6.7–6.9*
weight, 329
well-being, 329, 334
gestational age, 328, *Fig 6.4, Table 6.4*
gestational diabetes, 332, 352
intrauterine growth restriction, 330, *Box 9.3*
menorrhagia, 512, *Boxes 14.5, 14.6*
nuchal fold, 241
ovarian cysts, 492
pregnancy, 241, *Fig 6.6, Table 6.4*
pre-eclampsia, 343
umbilical cord, 234
prolapse, 333–8, *Fig 11.3*
ureter
cancer, *Table 16.3*
changes in pregnancy, 347
relationship to pelvic area, *Fig 18.1*
urinary fistulae, 549
urinary incontinence, 378, 544–51, 608–9, *Figs 15.14–5.18, Table 15.4*
cystometry, *Fig 15.17*
urinary symptoms, 318, 545
urinary tract infections, in pregnancy, 241, 318, 324
urodynamic studies, 549
uterine artery embolisation 491
uterovaginal prolapse, 541–4, *Figs 15.11–15.13*
uterine cervix; *see* cervix, uterine
uterus
abortion, 321
atonic, 265, 387
blood supply, 620, *Figs 1.3, 18.1*
congenital malformations, 171–3, *Fig 4.12*
miscarriage 320
contraction
Braxton Hicks, 248
suppression, 336
couvelaire, 385
development, 184
dysfunctional bleeding, 511
evacuation of contents, 322, 377, 378, 412, 627
fibroids, 486–91
infection, 377
inversion, 263, 389, *Fig 11.4*
lower segment, 623, *Fig 18.2*
perforation, 413, 627
postpartum involution, 295–6
prolapse, 541–4, *photo 145*
retraction, 254
rupture, 390
small/large for dates, 328, 331
trophoblastic disease, 322–4

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521818931 - Obstetrics, Gynaecology and Women's Health
Edited by Vivienne O'Connor and Gabor Kovacs
Index
More information

vacuum extraction 375, *Fig 10.3*
vagina
absence, photo 308
birth via, after caesarean, 365, 376, 390
bleeding postpartum, 378
cancer, 576–7
childhood development, 185
congenital malformations, 171–3, *Fig 4.12*
discharge, 185-6, 318, 421–6, *Table 12.5, photo 499*
cancer 565
douching, 415, 497
fistula, 549, 565, 568
infections, 185–6, 186–8, *Table 12.5*
pre-cancer, 558
prolapse, 541–4, *Fig 15.11*
stenosis, 579
vaginal examination, 16–18, *Figs 1.14, 1.16*
acute abdominal pain, 326
bleeding in pregnancy, 320, 385
contraindications, 336,
labour, 266
pregnancy, 27, 231, 237
vaginal intraepithelial neoplasia, *photo 502*
vaginismus, 18, 446–7
vaginosis, bacterial, 318
varicella in pregnancy, 229, 316
vasectomy, 407
ventouse delivery, 375, *Fig 10.3*
virus infection
HPV and cancer, 562
pregnancy, *Table 9.1*
sexually transmitted, 417
vitamin D, 78
vitamin K, 293–4, 346
vomiting in pregnancy, 331, 348–9
vulva
benign tumours, 435
cancer, 574–6, *photo 502*
infections, *Tables 12.7, 12.8*
lesions, *Table 12.7*
normal, *photo 145*
postmenopausal, *photo 145*
pre-cancer, 565
pruritus, 434
symptoms, 434–42
ulceration, 186, 436, *Table 12.9*
vulvovaginitis
in a child, 186–7
in an adult, 434, 441
vulvectomy, 575, 629

warts, genital, 429, *photo 499*
weight, 75–6, *Table 2.2*
energy, 77, *Table 2.3*
obesity, 80–1
pregnancy, 23, 224–5
women
and cancer, 595–7
caregiving and care needs, 138–9
medical problems, 625
minority groups, 63–68, 253
research and gender, 626, *Box 18.8*
screening of, 39, 61
surgical issues, 618, *Boxes 18.1, 18.2, Fig 18.1, Table 18.1*
the well woman, 506, *Box 14.1*
Wright-stained smear, *Box 12.12*

© Cambridge University Press www.cambridge.org